
Reference	Liebau, C., Petersen, W., Rembitzki, I.V.					
Products Major Findings	A clinical study on the effectiveness of a medial unloader brace (Agilium Reactive [®]) in patients with unicompartimental knee OA.					
	Eine klinische Studie zur Wirksamkeit einer medialen Entlastungsorthese (Agilium Reactive®) bei Patienten mit unikompartimenteller Gonarthrose					
	MOT: Medizinisch Orthopädische Technik 2017; 1: 32-36. Agilium Reactive					
						With Agilium Reactive:

WOMAC score

→ Significant improvements in all WOMAC sub-scores

Agilium Reactive showed significant improvements in all WOMAC subscores



WOMAC (n = 13)

T0= baseline; T1= after 4-week use of Agilium Reactive Significant improvements: *p = 0.003; **p = 0.043; ***p = 0.001


Patient satisfaction and compliance

- \rightarrow No or slight restrictions due to orthosis
- \rightarrow No or slight discomfort while wearing the orthosis
- \rightarrow Easy or learnable handling of the orthosis
- → Orthosis can be worn over long-time period
- \rightarrow Orthosis is recommended by the patients

Population	Subjects:	13 patients (6 male, 7 female)
	Mean age:	61.2 ± 15.9 years (range 41-91 years)
	Affected side:	left (4 patients); right (7 patients); both (2 patients)
	OA classification:	- grade I: 2 patients
		- grade II: 2 patients
		- grade III: 5 patients
		- grade IV: 4 patients
	Inclusion criteria:	- unicompartimental medial knee OA
		(Kellgren-Lawrence grade I-IV)
		- genu varum
		- older than 40 years
	Exclusion criteria:	- unicompartimental lateral knee OA

```
Study Design
```

Prospective before-and-after study with 4-week follow-up (with Agilium Reactive):



Results							
Functions and Activities Pa						Participation	
	omechanics – X-Ray iit analysis	EMG	Functional tests	Clinical effects	Satisfac	tion	
Category	Outcomes	Results for A	Agilium Reactiv	/e		Sig.*	
Clinical effects	WOMAC score	Baseline vs. 4-week follow-up					
	Pain sub-score	+ 19% (from 68 to 78 points)				· ++	
	Stiffness sub-score	+ 28% (from 68 to 78 points)				. ++	
	Physical function sub- score	+ 30% (from 64 to 77 points)				++	
Satisfaction	T	no	slight	moderate	strong	,	
	Restrictions	31%	54%	15%	0%	n.a.	
	Discomfort	46%	39%	15%	0%	n.a.	
	Handling	easy: 46% learnable: 54% difficult: 0%)%	n.a.	
	Long-term use	yes: 62%	reluctant: 38	3% no: 0%		n.a.	
	Recommendation	yes: 100%				n.a.	

Author's Conclusion

In summary, the presented results demonstrate the clinical evidence to justify the use of the Agilium Reactive[®] in patients with genu varum and medial knee OA.

"Zusammenfassend zeigen die vorgestellten Ergebnisse klinische Evidenz vor, um den Einsatz der Agilium Reactive[®] bei Patienten mit Genu varum und medialer Gonarthrose zu rechtfertigen." (Liebau et al. 2017)

© 2014, Otto Bock HealthCare Products GmbH ("Otto Bock"), All Rights Reserved. This article contains copyrighted material. Wherever possible we give full recognition to the authors. We believe this constitutes a 'fair use' of any such copyrighted material according to Title 17 U.S.C. Section 107 of US Copyright Law. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner. All trademarks, copyrights, or other intellectual property used or referenced herein are the property of their respective owners. The information presented here is in summary form only and intended to provide broad knowledge of products offered. You should consult your physician before purchasing any product(s). Otto Bock disclaims any liability related from medical decisions made based on this article summary.